期刊文献+

家兔宫颈注射荧光纳米颗粒盆腔淋巴结聚集性的实验观察

Observation on Pelvic Lymph Nodes Aggregation by Cervical Injection of Fluorescent Nanoparticles in Rabbits
下载PDF
导出
摘要 目的探讨NaYF4纳米颗粒宫颈注射后在家兔盆腔淋巴结聚集情况,并探讨聚集的最佳直径和最佳时间点。方法10%NaYF4纳米颗粒(Ф中20、50、100nm)溶液注射家兔宫颈,注射后(2、10、30、60、120min)分别取盆腔淋巴结制成切片,观察荧光颗粒的聚集情况,并用浓硝酸消化组织后定量检测NaYF4纳米颗粒浓度:10%50nm NaYF4纳米颗粒溶液注射家兔宫颈10min后取盆腔淋巴结、肝脏、肾脏和脾脏,并用浓硝酸消化组织后定量检测NaYF4纳米颗粒浓度。结果50nm是NaYF4纳米颗粒溶液注射家兔宫颈在盆腔淋巴结聚集的最佳直径,10min是最佳时间点:家兔盆腔淋巴结中NaYF4纳米颗粒的量大于肝、脾和肾等脏器的量。结论NaYF4纳米颗粒溶液经宫颈注射后能够在家兔的盆腔淋巴结中富集。 Objective To investigate whether there is enrichment of NaYF4 nano-particles in pelvic lymph node by cervical injection in rabbits, and also to decide the peak time and the best diameter of nano-particles. Methods 10% solution with different diameters of nano-particles (20, 50, 100 nm) is injected through female rabbit's cervix. The pelvic lymph nodes were be taken at different time (2, 10, 30, 60, 120 min) after injection and the aggregation peak of nano-particles were measured; in 10 min 50 nm group, the liver, spleen and kidneys are taken with pelvic lymph nodes together to detect the aggregation characteristics of nano-particles. Result The 50 nm is a preferable NaYF4 nano-particles diameter for NaYF4 solution injection through cervix, and 10 min is the peak time. Compared with the liver, spleen and kidneys, more nano-particles were aggregated in pelvic lymph nodes. Conclusion NaYF4 nanoparticle solution through cervical injection of the pelvic lymph nodes in rabbits can be enriched.
出处 《实验动物与比较医学》 CAS 2010年第3期180-182,187,共4页 Laboratory Animal and Comparative Medicine
关键词 NAYF4 纳米颗粒 家兔模型 生殖器肿瘤 淋巴结转移 淋巴富集 NaYF4 Nano-particles Rabbit model Genital cancer Lymph node metastasis Lymph concentration
  • 相关文献

参考文献11

二级参考文献53

  • 1[1]Look KY.Epidemiology,etiology,and screening of ovarian cancer.In:Rubin SC,Sutton GP,eds.Ovaian Cancer 2nd Ed Lippincott Williams and Wilkins,2001.167-180,201-218. 被引量:1
  • 2[2]Jacobs I.Discussion:ovarian cancer screening.Gynecol Oncol,2003,88:80-83. 被引量:1
  • 3[3]Xu Y,Shen Z,Wiper DW,et al.Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.JAMA,1998,280:719-723. 被引量:1
  • 4[4]Petricoin EF,Ardekani AM,Hitt BA,et al.Use of proteomic patterns in serum to identify ovarian cancer.Lancet,2002,359:572-577. 被引量:1
  • 5[5]Beverly R.Proteomic patterns in serum and identification of oavrian cancer.Lancet,2002,360:169. 被引量:1
  • 6[7]Ayhan A,Guvendag Guven ES,Guven S,et al.Recurrence and prognostic factors in borderline ovarian tumors.Gynecol Oncol,2005,98:439-445. 被引量:1
  • 7[8]Dexeus S.Labastida R,Dexeus D.Conservative management of epithelial ovarian cancer.Eur J Gynaecol Oncol,2005,26:473-478. 被引量:1
  • 8[9]Van der Burg M,Lent M,Buyse M,et al.The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer.New Eng J Med,1995,332:629-634 被引量:1
  • 9[11]Thigpen JT.Chemotherapy for advanced ovarian cancer:ovarview of randomized trials.Semin Oncol,2000,27(suppl 7):11-16. 被引量:1
  • 10[12]Ozols RF.Paclitaxel(Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.Semin Oncol,2000,27(suppl 7):3-7. 被引量:1

共引文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部